share_log

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8:员工福利计划证券登记
美股sec公告 ·  06/05 15:02
Moomoo AI 已提取核心信息
Clene Inc., a biopharmaceutical company, has filed a registration statement on Form S-8 with the Securities and Exchange Commission (SEC) on June 5, 2024. The filing is intended to register an additional 30 million shares of common stock under the Clene Inc. Amended 2020 Stock Plan. This move follows the approval by the company's Board of Directors on April 3, 2024, and by its stockholders on May 29, 2024, to increase the number of shares reserved for issuance from 18.4 million to 48.4 million. The registration statement includes references to prior filings and incorporates by reference the contents of the company's previous registration statements filed on March 29, 2021, and June 16, 2023. The company, headquartered in Salt Lake City, Utah, has designated Robert Etherington, its President and CEO, as the agent for service in this filing.
Clene Inc., a biopharmaceutical company, has filed a registration statement on Form S-8 with the Securities and Exchange Commission (SEC) on June 5, 2024. The filing is intended to register an additional 30 million shares of common stock under the Clene Inc. Amended 2020 Stock Plan. This move follows the approval by the company's Board of Directors on April 3, 2024, and by its stockholders on May 29, 2024, to increase the number of shares reserved for issuance from 18.4 million to 48.4 million. The registration statement includes references to prior filings and incorporates by reference the contents of the company's previous registration statements filed on March 29, 2021, and June 16, 2023. The company, headquartered in Salt Lake City, Utah, has designated Robert Etherington, its President and CEO, as the agent for service in this filing.
生物制药公司Clene Inc.在2024年6月5日向美国证券交易委员会(SEC)提交了S-8表格的注册申报。本次提交旨在注册Clene Inc.修改后的2020股票计划下额外的3000万股普通股。此举是继公司董事会于2024年4月3日和股东于2024年5月29日批准将发行股票数量从1840万股增加到4840万股后的开展。该注册申报包括对先前申报文件的参考,并通过引用公司于2021年3月29日和2023年6月16日提交的先前注册申报文件的内容来表达其含义。总部位于犹他州盐湖城的公司已指定其总裁兼首席执行官罗伯特·埃瑟灵顿为该申报的服务代理人。
生物制药公司Clene Inc.在2024年6月5日向美国证券交易委员会(SEC)提交了S-8表格的注册申报。本次提交旨在注册Clene Inc.修改后的2020股票计划下额外的3000万股普通股。此举是继公司董事会于2024年4月3日和股东于2024年5月29日批准将发行股票数量从1840万股增加到4840万股后的开展。该注册申报包括对先前申报文件的参考,并通过引用公司于2021年3月29日和2023年6月16日提交的先前注册申报文件的内容来表达其含义。总部位于犹他州盐湖城的公司已指定其总裁兼首席执行官罗伯特·埃瑟灵顿为该申报的服务代理人。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息